Nataliya L. Aleshenko

Nataliya L. Aleshenko

Auto-generated profile, based on publicly available information

Nataliya L. Aleshenko

Petrovsky National Research Center of Surgery

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2022 in Acta Naturae
Verified
Journal Article
Open access
PDF file
NKNikita Kostin
Nikita Kostin
TBT. V. Bobik
T. V. Bobik
GSG. A. Skryabin
G. A. Skryabin
MSMaria Simonova
Maria Simonova
VKV. D. Knorre
V. D. Knorre
AGAlexander Gabibov
Alexander Gabibov
Monitoring of the level of the virus-neutralizing activity of serum immunoglobulins ensures that one can reliably assess the effectiveness of any protection against the SARS-CoV-2 infection. For SARS-CoV-2, the RBD-ACE2 neutralizing activity of sera is almost equivalent to the virus-neutralizing activity of their antibodies and can be used to assess the level of SARS-CoV-2 neutralizing antibodies. We are proposing an ELISA platform for performing a quantitative analysis of SARS-CoV-2 RBD-neutralizing antibodies, as an alternative to the monitoring of the virus-neutralizing activity using pseudovirus or live virus assays. The advantage of the developed platform is that it can be adapted to newly emerging virus variants in a very short time (12 weeks) and, thereby, provide quantitative data on the activity of SARS-CoV-2 RBD-neutralizing antibodies. The developed platform can be used to (1) study herd immunity to SARS-CoV-2, (2) monitor the effectiveness of the vaccination drive (revaccination) in a population, and (3) select potential donors of immune plasma. The protective properties of the humoral immune response in hospitalized patients and outpatients, as well as after prophylaxis with the two most popular SARS-CoV-2 vaccines in Russia, were studied in detail using this platform. The highest RBD-neutralizing activity was observed in the group of hospitalized patients. The protective effect in the group of individuals vaccinated with Gam-COVID-Vac vaccine was 25% higher than that in outpatients and almost four times higher than that in individuals vaccinated with the CoviVac vaccine.

15 August 2024 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Closed access
PDF file
OGOlga B. Gordeeva
Olga B. Gordeeva
LNLeyla S. Namazova-Baranova
Leyla S. Namazova-Baranova
ADAlbina V. Dobrotok
Albina V. Dobrotok
NANatalia L. Aleshenko
Natalia L. Aleshenko
Background. There is evidence that platelet dysfunction in new-type coronavirus infection can lead to both thrombotic and hemorrhagic events: hypercoagulation syndrome leading to thrombosis is one of the most threatening complications of COVID-19; equally important is the hemorrhagic syndrome that can be observed after this disease. The study of platelet aggregation function in children with new-onset coronavirus infection is highly relevant: the results of aggregometry in pediatric practice may help to predict the development of complications from vascular and platelet hemostasis. Aims — to evaluate the direction of changes in platelet haemostasis in children undergoing COVID-19. Methods. In the first phase of the work, we clarified the normal values of platelet aggregation in children with different inducers in whole blood by impedance testing (based on examination data from 105 conditionally healthy children who had not had COVID-19). At the second (main) phase of the study we conducted a single-stage prospective study including 250 pediatric patients residing in the Russian Federation: 143 children suffered mild COVID-19, while the comparison group consisted of 107 patients who had not been ill with a new-type coronavirus infection. All children (those who had COVID-19 and those who had no disease) underwent a comprehensive examination, which included: physical examination, aggregometry and laboratory tests (to rule out acute inflammatory process and hemogram abnormalities potentially affecting platelet aggregation rates). Results. Almost half of the patients after COVID-19 had platelet aggregation abnormalities. At the same time, in every third child there were combined multidirectional disorders in the form of hypo- and hyperaggregation with different inducers, in contrast to the group of children who did not have COVID19 (p 0.05). In the COVID19 group aggregation abnormalities with arachidonic acid were most frequently detected: almost every second patient had hyperaggregation and every fourth patient had hypoaggregation, which was statistically significantly different from the non-disease group (p 0.05). Analysis of the results depending on the time interval after the disease (1–3 months, 3–6, 6–12 months, more than 12 months) showed platelet hyperaggregation with all inducers at 1–3 months, and there was a tendency to reduce aggregation with thrombin and ADP, but hyperaggregation with arachidonic acid persisted for one year after the disease. At an interval of more than one year after COVID-19 every second patient showed a decrease in platelet function (hypoaggregation with all inducers). No statistically significant differences by gender were observed depending on the time interval after the infection. Conclusions. The results of the study demonstrate the vectors of impaired vascular and platelet hemostasis in children with mild COVID-19: The time intervals of platelet dysfunction after the disease have been determined. The results of the study may help to develop a surveillance strategy for children who have had a new type of coronavirus infection to prevent the development of complications from vascular and platelet hemostasis.

2 December 2025 in Pediatric pharmacology
Verified
Journal Article
Closed access
SGSvetlana G. Gubanova
Svetlana G. Gubanova
ASAndrey N. Surkov
Andrey N. Surkov
IZIrina V. Zelenkova
Irina V. Zelenkova
LNLeyla S. Namazova-Baranova
Leyla S. Namazova-Baranova
VGViktor A. Gankovskii
Viktor A. Gankovskii
MIMarika I. Ivardava
Marika I. Ivardava
Background. The management of patients with multifactorial autoimmune diseases (inflammatory bowel diseases (IBD) and chronic dermatoses) is currently impossible without taking into account the clinical and biological phenotypes of the disease. To develop optimal disease control, it is necessary to study the factors that influence the manifestation, course, and relapse of the diseases. In addition, it is required to understand the phenotypic clinical and immunological parameters of inflammation, which depend on the underlying pathological process, the therapy, and the condition of other organs and systems involved in the underlying pathological process, including the upper respiratory tract. The aim of the study was to determine the main phenotypic clinical and immunological parameters of inflammation in pediatric patients with immune-inflammatory diseases associated with upper respiratory tract pathology (using psoriasis and IBD as an example). Methods. The study included 60 children: 20 patients with psoriasis and 20 children IBD, as well as 20 patients in the control group (conditionally healthy children) aged 6 years to 17 years 11 months. All patients in the study groups were consulted by a pediatrician, an otolaryngologist, an audiologist, and an allergist (if indicated). Patients with psoriasis were examined by a dermatologist, and children with IBD were examined by a gastroenterologist. Instrumental examination methods included nasal and nasopharyngeal endoscopy, otoscopy, tympanometry, and tonal threshold audiometry. Laboratory methods of research: clinical blood test, determination of antistreptolysin O, IL-1α, IL-1β, IL-6, IL-7, IL-8, IL-10, IL-12, IL-15, IL-17, IL-18, IL-19, IL-20, IL-23, and TNF-α levels in blood serum; determination of serum proteins (MDC/CCL22) and TLSP/kallikrein in blood serum. All patients in the target groups underwent rapid fecal testing for Helicobacter pylori and microbiological studies (mycological examination of oropharyngeal discharge for Candida albicans fungi; bacteriological examination of nasopharyngeal discharge for Staphylococcus aureus; and examination of intestinal microbiocenosis). Results. The obtained data allow us to identify the leading comorbid pathology of the upper respiratory tract in both study groups was chronic tonsillitis. Analysis of the intestinal microbiota composition revealed an imbalance of commensals and pathobionts in both children with IBD and patients with psoriasis. Immunologically, the presence of chronic tonsillitis in children with IBD was accompanied by increased levels of IL-23 and MDC/CCL22, while in patients with psoriasis it was accompanied by increased levels of IL-18 (p < 0.05). Another association identified for children with psoriasis — with allergic rhinitis — was also characterized by a significant increase in IL-18 (p < 0.05). The immunophenotype of IBD patients demonstrated an increase in IL-23 (p < 0.05), while in children with psoriasis, an increase in IL-18 (p < 0.05). Conclusion . At this stage of the study, the primary clinical and immunological markers of inflammation phenotypes in children with autoimmune diseases (using the example of psoriasis and IBD) and their relationship with the presence of comorbid pathology of the upper respiratory tract have been obtained. The study is currently ongoing; the results of this work will help improve the principles of managing children with immune-inflammatory pathology.

4 July 2024 in Pediatric pharmacology
Verified
Journal Article
Open access
PDF file
SGSvetlana G. Gubanova
Svetlana G. Gubanova
EAEduard T. Ambarchyan
Eduard T. Ambarchyan
LNLeyla S. Namazova-Baranova
Leyla S. Namazova-Baranova
EVElena A. Vishneva
Elena A. Vishneva
IZIrina V. Zelenkova
Irina V. Zelenkova
VIVladislav V. Ivanchikov
Vladislav V. Ivanchikov
Psoriasis is the second most common skin disease after atopic dermatitis in childhood. There are factors affecting both the manifestation and aggravation of this inflammatory skin process. The leading role in the psoriasis pathogenesis is currently associated with key cytokines. However, infectious diseases could be the triggers for psoriasis.Nowadays, the approach to psoriasis management in children has been revised due to emerging of new knowledge about the clinical manifestations and the role of numerous comorbid conditions in psoriasis course. Risk factors assessment, as well as evaluation of potential comorbidities signs and symptoms, is crucial part in patient management to create a prognostic model of the disease progression and the aggravation development (with underlying associated inflammatory processes included).

23 July 2026 in Pediatric pharmacology
Verified
Journal Article
Open access
PDF file
NVNato D. Vashakmadze
Nato D. Vashakmadze
NZNataliya V. Zhurkova
Nataliya V. Zhurkova
NSNataliya A. Sholokhova
Nataliya A. Sholokhova
NSNataliya S. Shatokhina
Nataliya S. Shatokhina
DMDmitriy M. Munov
Dmitriy M. Munov
LKLarisa P. Kiselnikova
Larisa P. Kiselnikova
Background. Hypophosphatasia (HPP) is a hereditary disorder belonging to the group of mineral metabolism disturbances, caused by deficiency of tissue-nonspecific alkaline phosphatase due to pathogenic and likely pathogenic variants in the ALPL gene. It is characterized by a wide spectrum of clinical manifestations, ranging from severe perinatal phenotypes to milder forms presenting in childhood and adulthood. Early loss of primary teeth, and later of permanent teeth, is often the first symptom of HPP but remains underestimated. HPP is not always recognized by physicians, especially in mild cases. The importance of radiological diagnostics in identifying all forms of HPP should be emphasized. Currently, with the availability of effective pathogenetic therapy, early diagnosis is of particular importance, as it allows the disease to be identified before life-threatening conditions develop. Case series. This article presents a case series of both severe HPP with manifestation at birth and milder forms involving dental and skeletal system involvement. Enzyme replacement therapy stabilized the condition of a patient with the severe perinatal form, as well as two patients with the childhood form of HPP, in whom early loss of primary teeth was the first clinical sign of the disease. Of particular interest is the description of a familial case involving the patient’s mother, who had clinical manifestations of HPP in early childhood, but the diagnosis was only established during the evaluation of her son. Conclusion . Effective pathogenetic therapy has been developed for HPP, which improves the health status of patients. Early diagnosis and timely initiation of treatment will help preserve health and, in severe cases, save patients’ lives.

1 January 2022 in Infectious diseases: News, Opinions, Training
Verified
Journal Article
Closed access
GIG.M. Ignatyev
G.M. Ignatyev
LKLiubov Kozlovskaya
Liubov Kozlovskaya
KMK.M. Mefed
K.M. Mefed
VVViktor Volok
Viktor Volok
IBI.Kh. Belyaletdinova
I.Kh. Belyaletdinova
AIAydar A. Ishmukhametov
Aydar A. Ishmukhametov
Определение антител к вирусу SARS-СoV-2 у пациентов с новой коронавирусной инфекцией